SpectrumDNA Stock

SpectrumDNA P/S

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of SpectrumDNA (SPXA) as of Jul 17, 2026.

P/S

0.00

Last updated:

As of Jul 17, 2026, SpectrumDNA's P/S ratio stood at 0.00, a % change from the - P/S ratio recorded in the previous year.

The SpectrumDNA P/S history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/S
Date
P/S
Jan 1, 2006
0.00 base
Jan 1, 2007
0.00 base
Jan 1, 2008
0.00 base
Jan 1, 2009
49.17 base
Jan 1, 2010
4.80 base
YEARP/S
2010 4.80
2009 49.17
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

SpectrumDNA Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides SpectrumDNA's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates SpectrumDNA's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots SpectrumDNA's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if SpectrumDNA grows earnings faster than its peers.

SpectrumDNA Stock analysis

What does SpectrumDNA do? SpectrumDNA Inc is a company specializing in the development and marketing of genetic tests and analyses. Founded in 2013, the company is based in Austin, Texas and is one of the leading companies in the field of DNA analysis. The history of SpectrumDNA goes back to its founders, Dr. Jamie Teumer and Dr. João Silveira. Both bring years of experience in genetics and molecular biology and have worked on numerous research projects. Their goal was to make genetics accessible to everyone and improve healthcare. With this drive, they founded SpectrumDNA and began to put their idea into action. SpectrumDNA's business model is based on the creation of genetic tests and analyses that allow people to know their personal risk for certain diseases or conditions and take targeted preventive measures. SpectrumDNA works closely with doctors and other healthcare experts to interpret and implement the results and recommendations of the tests. SpectrumDNA offers a variety of genetic tests and analyses targeting various areas of health and well-being. These include tests for identifying genetic risk factors for cancer, cardiovascular diseases, Alzheimer's, and Parkinson's, as well as tests for predicting behavioral traits and physical characteristics such as lactose intolerance or hair color. The company also has its own research and development department that constantly works on advancing and improving test methods and technologies. This ensures that customers at SpectrumDNA always receive the latest and most accurate information. SpectrumDNA has also specialized in developing products based on the genetic profiles of its customers. These include personalized supplements tailored to the individual needs of the customer, as well as personalized training plans based on the customer's genetic traits. Recently, SpectrumDNA has also focused its attention on the application of genetics in the beauty industry. The company has developed a procedure that allows the analysis of skin quality and aging process based on the customer's genetic profile. Based on this analysis, a personalized skincare program is created that is tailored to the individual needs and goals of the customer. Overall, SpectrumDNA is a leading company in the field of DNA analysis and specializes in personalized healthcare services. Through close collaboration with doctors and other healthcare providers, as well as constant advancement and improvement of its technologies and products, SpectrumDNA enables its customers to improve their health and well-being in a personalized and effective way. SpectrumDNA is one of the most popular companies on Eulerpool.

P/S Details

Decoding SpectrumDNA's P/S Ratio

SpectrumDNA's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing SpectrumDNA's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating SpectrumDNA's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in SpectrumDNA’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about SpectrumDNA stock

On Eulerpool you can find the complete historical development of (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. SpectrumDNA since 2006 – with annual values, charts, and detailed analysis.

The P/S ratio when valuing a stock.

The price-to-sales ratio (P/S ratio) is an important tool of technical analysis that assists investors in evaluating stocks. It refers to the earnings per share of a company and its price movements. This indicator can be used to determine a stock's fair value, relative to the company's earnings.

History of the Price-to-Sales Ratio

The price-to-sales ratio is a relatively new indicator. It was first used in the 1980s by John Price when he developed the Price-to-Sales Index (PSI). Price wanted to find a way to value stocks taking into account their earnings. He noticed that many stock prices were not in line with their earnings situation. The PSI has since become an important analytical tool and is often referred to as the P/S ratio.

Calculation of the price-to-sales ratio

The price-to-sales ratio is easy to calculate. It is determined by dividing the current stock price by the company's earnings per share. P/S ratio = Stock price / Earnings per share. For example, if a company's stock price is $10 and the earnings per share is $2, then the P/S ratio is 5.

Application of the Price-to-Sales Ratio

The Price-to-Sales ratio is a useful tool for determining a fairly valued stock price. A low P/S ratio may indicate that a stock price is undervalued, which could be a good entry opportunity. However, a high Price-to-Sales ratio may indicate that a stock price is overvalued and investors should exercise caution.

An example: A company has a stock price of 20 USD and an earnings per share of 2 USD. The P/E ratio is 10. This could indicate that the stock price is overvalued and investors should be cautious before buying.

Investors and the price-to-sales ratio

Investors use the price-to-sales ratio to determine whether a company's stock price is fairly valued or not. They can compare the P/S ratio to see how the stock price relates to the company's earnings. Investors can also observe the P/S ratio over a longer period of time to see if the stock price changes in relation to the company's earnings.

Advantages and Disadvantages of the Price-to-Sales Ratio

The greatest advantage of the price-to-sales ratio is that it is a simple and understandable tool to determine the fair value of a stock price. It can also help investors identify stocks that are undervalued. One disadvantage is that the P/S ratio does not provide information about the company's profits. Therefore, investors should also consider other financial ratios before investing.

In today's time, the price-to-sales ratio is an important tool for investors to evaluate stocks and identify potential investment opportunities. It can help find a fairly valued stock price and identify stocks that are undervalued. However, investors should also consider other financial indicators before making an investment decision.

Access this data via the Eulerpool API

Valuation — SpectrumDNA

All Key Metrics — SpectrumDNA